// App-Quantinova.ai

277 : Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs

Researchers

Presenter

  • Xavier Mariette

Principal Investigators

  • Sandrine Aspeslagh

  • Richard Moriggl

  • Vijay Rajendran

  • Christine Rudolph

  • Paul Van Hoek

  • Nadia Verbruggen

  • Christopher Watson

  • Sven Borchmann

  • Andreas Stallmach

Medical Centers

  • Paris-Saclay University, Rueil Malmaison, Ile-de-France, France

  • UZ Brussel, Brussel, Belgium

  • University of Veterinary Medicine Vienna, Vienna, Austria

  • Galapagos NV, Gent, Belgium

  • Galapagos, Mechelen, Belgium

  • Galapagos Biotech Ltd, Cambridge, United Kingdom

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • Clinic for Internal Medicine IV, Jena University Hospital, Jena, Germany

Locations

  • France

  • Belgium

  • Austria

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Oncology (ONC)

Disease

  • Rheumatoid arthritis

  • Ulcerative colitis

  • Skin carcinoma

  • Inflammatory Arthritis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02092467

  • NCT01894516

  • NCT02065700]

  • NCT02873936

  • NCT02886728

  • NCT03025308]

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved